EBOS Group Limited (ASX:EBO): What Do FY26 Earnings and Distribution Investments Signal?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

EBOS Group Limited (ASX:EBO): What Do FY26 Earnings and Distribution Investments Signal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EBOS Group (ASX:EBO) reported AUD 13.49 billion Revenue in FY26, up 9.9%.
Underlying EBITDA increased 5.0% to AUD 614 million.
The AUD 360 million distribution centre renewal programme is complete.
FY27 underlying EBITDA guidance stands at AUD 635–655 million.

EBOS Group Limited (ASX:EBO) distributes pharmaceutical, medical and healthcare products and operates animal-care businesses across Australasia and selected Asian markets. Shares in EBOS (ASX:EBO) were priced at AUD 17.70 on 12 November 2026, a gain of 0.68% for the session. The company’s 2026 developments centre on its completed distribution infrastructure renewal, growth in healthcare and animal care activities, and recently published FY27 financial expectations.

Healthcare Distribution and Animal Care

The EBOS (ASX:EBO) portfolio spans community pharmacy distribution, hospital medicines, medical technology, contract logistics, retail pharmacy brands and animal care. Its healthcare activities serve pharmacies, hospitals and other providers, while its animal-care operations include wholesale distribution and branded pet products. The group operates across Australia, New Zealand and parts of Southeast Asia. These divisions have different gross margins and operating requirements, so group revenue alone does not describe profitability equally across every activity.

Within healthcare, EBOS reported FY26 community pharmacy revenue of AUD 7.1 billion, increasing 10.2%. Its pharmacy Brand network reached 780 stores, including MediAdvice and other banners. TerryWhite Chemmart network sales rose 9.2% to approximately AUD 2.9 billion. Medical technology also contributed growth, with reported revenue increasing 5.5%, or 8.4% in constant currency. Those figures describe different Business measures and should not be aggregated.

FY26 Distribution and Acquisition Developments

During FY26 EBOS (ASX:EBO) completed a four-year distribution centre renewal programme costing AUD 360 million. The major facilities are now operational, moving management attention towards Warehouse utilisation, productivity and financial returns rather than construction. The group also expanded through acquisitions in animal care and medical technology. Its Paringa Pet Foods acquisition, executed during FY26, completed in July 2026.

The company identified improvements at its Kemps Creek distribution centre as an operating priority. It is targeting a 30% productivity uplift against the prior site by the end of FY27, which remains a target rather than a realised result. Its Perth contract logistics Facility is also online. These initiatives matter because distribution capacity must be translated into efficient throughput before its costs can be assessed fully.

Financial Performance and FY27 Expectations

EBOS (ASX:EBO) reported FY26 revenue of AUD 13,487 million, compared with AUD 12,267 million a year earlier. Underlying EBITDA rose 5.0% to AUD 614 million, while underlying net profit after tax declined 3.1% to AUD 250 million. Statutory net profit increased 4.7% to AUD 225 million. The divergence between underlying operating Earnings and profit reflects depreciation, Amortisation and financing costs associated with the Investment cycle.

Healthcare revenue reached AUD 12,580 million, with underlying EBITDA of AUD 516 million. Animal Care revenue increased 34.6% to AUD 907 million, with underlying EBITDA of AUD 138 million. Group Leverage was 2.1 times, within the stated target band of 1.7 to 2.3 times. EBOS maintained a final Dividend of NZ 61.5 cents per share.

For FY27, management guided to underlying EBITDA of AUD 635–655 million and Capital Expenditure of approximately AUD 100 million. It also indicated Depreciation and amortisation of about AUD 152–162 million and net finance costs of approximately AUD 138–148 million. These are management expectations, not completed financial outcomes.

Risks and Operational Milestones

Wholesale pharmacy competition, changing medicine mix, transport costs and foreign exchange exposure can affect EBOS (ASX:EBO) margins. Higher depreciation and finance expense can also constrain profit even when earnings before those items increase. Newly commissioned distribution sites require operating discipline to achieve their planned capacity and efficiency benefits. Acquisition integration presents another execution consideration.

What to Watch Next

Future EBOS (ASX:EBO) reporting can clarify Kemps Creek productivity, pharmacy wholesale margins, medical technology sales and animal-care product growth. Investors may also monitor whether FY27 capital expenditure moves towards the company’s indicated level and whether group leverage remains inside its target band. The distinction between underlying EBITDA growth and net profit remains relevant.

Key Insights

EBOS (ASX:EBO) enters FY27 following a year of revenue growth and completion of its distribution centre investment programme. Underlying EBITDA increased, whereas underlying net profit decreased. Management’s current guidance centres on higher EBITDA and lower capital expenditure, with execution, cost pressures and funding costs remaining measurable considerations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.